Focus Areas in the Genomic Medicine Cycle
Major leadership positions
Chief, Division of Neurocritical Care
Faculty, Center for Genomic Medicine
MGH Unit(s)
Neurology
MGH Dept/Division/Unit(s)
Division of Neurocritical Care
Overview
Diagnostic tools and therapies for brain injury
The Kimberly Lab is committed to reducing the devastating effects of acute brain injury by focusing on translational studies that bridge basic science and clinical research. We believe that therapeutic discovery is not a linear path from fundamental mechanism to new drug, but instead a cycle that requires bi-directional and multidisciplinary integration of basic and patient-oriented research. A presence at each stage of discovery—both directly and through strategic collaboration—is central to our mission to advancing new treatments. Consequently, our laboratory is highly multidisciplinary and collaborative, and our work could not be accomplished without our collaborative partners.
Priority Projects
- Intravenous glibenclamide for the prevention of brain edema
- Post-stroke neuroinflammation and brain injury
- Gut-brain axis and risk of stroke
- Portable, low-field MRI imaging in critically ill patients
Lab Members
| Name: | Role: |
|---|---|
| Riana Schleicher, BA | Clinical Research Coordinator |
| Zsuzsanna Ament, PhD | Clinical Research Coordinator |
| Naruchorn Kijpaisalratana, MD | Research Fellow |
| Matthew Bevers, MD, PhD | Assistant Professor of Neurology |
| Caroline Booraem, BA | Clinical Research Coordinator |
| Morgan McKeown, BA | Clinical Research Coordinator |
| Varun Bhave, AB | Harvard Medical Student |
| Ana-Lucia Garcia Guariz, MD | Neurology resident |
The Center for Genomic Medicine (CGM) comprises one of the largest and most vibrant hubs of genomic medicine research in the world. The CGM includes 46 faculty collaborating to define the ‘genomic medicine cycle’ – which envisages a genomics community seeking to advance research from basic genomics research to ultimately using genome information for diagnostics and targeted therapeutics. All of our investigators are faculty at Harvard Medical School, and many members of our community are also investigators at the Broad Institute of Harvard and MIT.
